VANFLYTA 17.7mg tablets medication leaflet

L01EX11 quizartinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors

General data about VANFLYTA 17.7mg

Substance: quizartinib

Date of last drug list: 01-02-2026

Commercial code: W71641001

Concentration: 17.7mg

Pharmaceutical form: tablets

Quantity: 28

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: DAIICHI SANKYO EUROPE GMBH - GERMANIA

Holder: DAIICHI SANKYO EUROPE GMBH - GERMANIA

Number: 1768/2023/02

Shelf life: 5 years

Concentrations available for quizartinib

17.7mg, 26.5mg